Sun Pharmaceutical Industries scrip rose Rs 32 or 2.3 per cent to close the day at Rs 1,429.20 on reports of US Food and Drug Administration’s (USFDA’s) nod for a generic drug.
The company is believed to have received final approval to market Caffeine Citrate in injection and oral solution. The stock opened at Rs 1,397 and made an intra-day high of Rs 1,441.70. The stock is trading 11 per cent lower than its 52-week high of Rs 1,600 reached on 19 May, 2009.
Content Guide
